Skip to main content

Table 2 Interaction analyses for double-inhibitory KIR and KIR ligand genotypes with TTRF

From: Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab

 

TTRF

Line

Treatment

Genotype Group

Number of Events/n

4 yr Fail Rate (95% CI)a %

Interaction p-value

1

Maintenance

KIR2DL1+/C2+ and KIR3DL1+/Bw4+

17/44

37 (24–54)

0.694

2

Maintenance

not KIR2DL1+/C2+ and KIR3DL1+/Bw4+

11/36

34 (19–55)

3

Non-Maintenance

KIR2DL1+/C2+ and KIR3DL1+/Bw4+

10/32

33 (18–54)

4

Non-Maintenance

not KIR2DL1+/C2+ and KIR3DL1+/Bw4+

14/47

31 (19–48)

5

Maintenance

Group 1: KIR2DL2+/C1+ and KIR3DL1+/Bw4+

9/22

45 (24–72)

0.068

6

Maintenance

Group 2: not KIR2DL2+/C1+ and KIR3DL1+/Bw4+

19/58

32 (21–47)

7

Non-Maintenance

Group 1: KIR2DL2+/C1+ and KIR3DL1+/Bw4+

4/23

17 (6–44)

8

Non-Maintenance

Group 2: not KIR2DL2+/C1+ and KIR3DL1+/Bw4+

20/56

38 (26–54)

9

Maintenance

KIR2DL3+/C1+ and KIR3DL1+/Bw4+

12/35

38 (26–54)

0.447

10

Maintenance

not KIR2DL3+/C1+ and KIR3DL1+/Bw4+

16/45

34 (21–51)

11

Non-Maintenance

KIR2DL3+/C1+ and KIR3DL1+/Bw4+

10/37

25 (13–44)

12

Non-Maintenance

notT KIR2DL3+/C1+ and KIR3DL1+/Bw4+

14/42

38 (24–57)

  1. a95% Confidence interval; lines 5-8 (bolded text) had a p-value <0.100 and were analyzed further for associations with outcome